# KLOW Peptide Benefits in the Component Research — KLOW peptide > KLOW peptide benefits are documented only at the component level — GHK-Cu collagen and gene data, BPC-157 tendon repair, TB-500/thymosin beta-4 wound healing, KPV anti-inflammation. None is proven for the untested blend. Every benefit on this page is cited to a single constituent. None is a proven property of the four-peptide blend, which has not been tested. ## The gist When people search for KLOW peptide benefits, the honest answer is that the benefits live in four separate piles of research — one per peptide — and not in any study of the four together. So this page reads each pile plainly and keeps the label on it. GHK-Cu has skin, collagen and gene-expression data, some of it from topical human studies. BPC-157 has a deep record of rodent tendon and gut repair. TB-500's strength borrows from studies of the full protein it comes from, thymosin beta-4, which sped wound healing in rats. KPV calms inflammation in cells and animal gut. Each is real on its own terms. None of it proves anything about the blend, because [what the component research shows](/research) is exactly that — component research. ## GHK-Cu: the matrix and skin benefits GHK-Cu carries the deepest human-adjacent benefit record of the four. It stimulates synthesis of collagen and the proteoglycans dermatan sulfate, chondroitin sulfate and decorin, and in one comparison topical GHK-Cu increased collagen production in 70% of treated women, versus 50% for vitamin C and 40% for retinoic acid, with placebo-controlled improvements documented in skin laxity, clarity, fine lines, wrinkle depth and density [4]. At the gene level it modulates roughly 31.2% of human genes at a 50%-or-greater threshold, favoring tissue-repair, antioxidant and DNA-repair programs [5]. Plasma GHK falls from about 200 ng/mL at age 20 to about 80 ng/mL by 60, which frames the cosmetic interest [4]. These are GHK-Cu benefits — not blend benefits. ## BPC-157 and TB-500: the repair and wound benefits BPC-157's benefit record is anchored in rodent tissue repair: in a fully transected rat Achilles tendon it accelerated healing across biomechanical, functional and microscopic measures [2], and a 2025 human safety pilot found intravenous BPC-157 up to 20 mg well tolerated in two adults — a safety signal, not an efficacy result [12]. TB-500 is a fragment of thymosin beta-4, the protein that increased wound re-epithelialization by 42% at 4 days and 61% at 7 days in rats and stimulated keratinocyte migration at as little as 10 picograms [1]; thymosin beta-4 also activated hair-follicle stem cells to increase hair growth in rodents [6][9]. The fuller benefits belong to the native protein, not automatically to the short fragment in the vial. ## KPV: the anti-inflammatory benefit KPV's documented benefit is anti-inflammatory. At nanomolar concentrations it is taken up via PepT1 into gut and immune cells and inhibits NF-kappaB and MAP-kinase signaling, lowering pro-inflammatory cytokine output; oral KPV reduced the severity of chemically induced colitis in mice [3]. It is the constituent that distinguishes KLOW from the KPV-free GLOW blend, and the one community accounts most often credit with a "less inflamed" feeling — though that comparison is subjective, not a study. See the [KLOW vs GLOW comparison](/klow-vs-glow) for how that difference reads on the record. ## What "documented" means here, and what it does not A benefit is recorded on this page only when a named study measured it for a named constituent. That bar matters because the gap between "a peptide in KLOW has this benefit" and "KLOW has this benefit" is the whole subject. GHK-Cu's collagen and skin results are documented in humans [4]; BPC-157's tendon results are documented in rats [2]; thymosin beta-4's wound and hair results are documented in rodents [1][6]; KPV's anti-inflammatory results are documented in cells and mice [3]. Each is real evidence for its own peptide. None of it transfers to the four mixed together by addition, because mixing can change exposure, stability and interaction in ways only a combination study could show. The catalogue keeps the label on every benefit so a reader never mistakes a constituent result for a blend result. ## The gut and delivery research, in context Several of KLOW's component benefits sit in the gut and wound-delivery literature, which is worth flagging since community reports often mention digestive comfort. KPV's anti-inflammatory action was shown in models of chemically induced colitis [3], and newer delivery work — a mucoadhesive hydrogel capturing KPV [13], a polyglutamic-acid hydrogel stabilizing it for inflammatory-bowel-disease research [14], and a 2024 KPV-rapamycin carrier-free nanodrug [15] — illustrates active interest in getting the tripeptide to inflamed tissue. BPC-157, too, was originally developed as PL 14736 for inflammatory bowel disease. These are component-level, mostly preclinical findings; they make the gut-comfort theme in anecdotal reports plausible, but they are not a tested benefit of the blend. ## What are the benefits of the KLOW peptide blend? Benefits are documented only at the component level: GHK-Cu has collagen-synthesis and topical human skin and hair data, BPC-157 has extensive rodent tendon and gut-repair data, TB-500/thymosin beta-4 has wound and cell-migration data, and KPV has anti-inflammatory and gut-mucosa data. None of these is a proven property of the four-peptide blend, which has not been tested in any controlled study [11]. A reader is on the firmest ground treating each benefit as belonging to its single peptide, and the combined benefit as unrecorded. --- A monumental catalogue of the four-peptide KLOW record, inscribed per constituent with the unwritten blend study left a plainly marked lacuna — not a clinic, not an apothecary, not a prescription.